PharmAlert.net

PharmAlert Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Neurobase.it

A meta-analysis of published data was conducted to investigate the overall risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer ( NSCLC ) who were receiving ...


The Food and Drug Administration ( FDA ) is requiring that the manufacturers of all approved prescription Testosterone products change their labeling to clarify the approved uses of these medications. ...


Researchers at University of Bologna ( Italy ) have assessed the hepatic safety of Novel Oral AntiCoagulants ( NOACs ) analyzing the publicly available US-FDA Adverse Event Reporting System ( FAERS ). ...


It remains unclear whether Dabigatran etexilate mesylate ( Pradaxa ) is associated with higher risk of bleeding than Warfarin sodium ( Coumadin ) in real-world clinical practice. A study has compar ...


In the EU ( European Union ), Zydelig ( Idelalisib ) is indicated in combination with Rituximab ( MabThera ) for the treatment of adult patients with chronic lymphocytic leukemia who have received at ...


Testosterone therapy for older men has increased substantially over the past decade. Research on the effects of Testosterone therapy on cardiovascular outcomes has yielded inconsistent results. A s ...


Eltrombopag ( United States: Promacta; Europe: Revolade ), in addition to the approval for severe aplastic anemia in the U.S., is indicated for the treatment of thrombocytopenia in patients with: chro ...


Ipilimumab ( Yervoy ) is a novel FDA-approved recombinant human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 and has been used to treat patients with metastatic melanoma. Immun ...


Cerdelga ( Eliglustat ), a novel glucosylceramide analog given orally, was designed to partially inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucosylceramide. ...


Apremilast ( Otezla ) is an oral small-molecule inhibitor of phosphodiesterase 4 ( PDE4 ) specific for cyclic adenosine monophosphate ( cAMP ). PDE4 inhibition results in increased intracellular cAMP ...


There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking Januvia ( Sitagliptin ). After initiating Sitaglip ...


A review of the latest evidence on the risk of thromboembolism in association with combined hormonal contraceptives ( CHCs ) has concluded that: a) the risk of blood clots with all low-dose CHCs is sm ...


There is an increased risk of tuberculosis, or reactivation of latent tuberculosis, during treatment with tumour necrosis factor alpha ( TNF-alpha ) inhibitors. Tuberculosis in patients receivin ...


Voriconazole ( Vfend ) is known to be associated with a risk of liver toxicity, phototoxicity, and squamous cell carcinoma of the skin. Liver function before starting treatment with Voriconazole sho ...


Domperidone ( Motilium ) is associated with a small increased risk of serious cardiac side effects. Its use is now restricted to the relief of nausea and vomiting and the dosage and duration of use ha ...